In 2025, at the prestigious 34th Economic Forum in Karpacz, a panel discussion titled ‘Drug safety and competitiveness of the pharmaceutical industry in the new geopolitical reality’ brought together key figures in the European pharmaceutical landscape. The focus was on finding the delicate balance between fostering innovation, ensuring drug safety, and maintaining competitiveness in the face of global challenges. The conversation delved into topics such as the evolving role of the state in healthcare, the impact of market mechanisms on drug accessibility, and the intricate dance between national sovereignty and international solidarity.
Adam Jarubas, a distinguished Member of the European Parliament (MEP) and Chair of the Committee on Public Health (SANT), set the stage for the discussion by shedding light on the significant legislative efforts happening at the EU level. He highlighted the monumental pharmaceutical package, the most substantial reform in the medicines market in two decades, which aims to revolutionize the sector’s landscape. The Polish Presidency’s success in garnering support from Member States for this reform was underscored, paving the way for tripartite negotiations with the European Parliament and Commission.
Key to this reform is the act on critical medicines, a vital component in ensuring Europe’s self-sufficiency in essential drugs. Additionally, the forthcoming act on biotechnology aims to streamline regulations for biological medicines, crucial in an era of rapid advancements in healthcare. Jarubas emphasized the importance of striking a balance between innovation and generic medicines to fortify Europe’s pharmaceutical sector effectively.
Barbara Misiewicz-Jagielak, Director for Public Relations at Polpharma, brought attention to the critical need for Europe to reduce its dependence on medicines and active substances sourced from Asia. She advocated for increased production of essential drugs within Europe, stressing the importance of coordinated efforts among countries to bolster local manufacturing capabilities. The disruptions caused by the pandemic served as a stark reminder of the vulnerabilities stemming from overreliance on external sources for medicines.
Dr. Monika Raulinajtys-Grzybek, from the SGH for Health think tank, added a strategic perspective to the discussion, outlining the considerations for drug safety in the context of potential armed conflicts. She highlighted the importance of securing the production and transport of medicines during tumultuous times, underscoring the interplay between healthcare and national security.
Wiktor Janicki, President of AstraZeneca Pharma Poland, drew attention to the widening investment gap between the European Union and the United States. He stressed the necessity of regulatory initiatives, such as the Biotech Act, to equip Europe for upcoming medical innovations like cell and gene therapies. Janicki emphasized that a stable investment environment, bolstered by strong legal frameworks and intellectual property protection, is crucial for enhancing competitiveness in the pharmaceutical sector.
On the topic of competitiveness, Janusz Cieszyński, former deputy health minister, expressed skepticism regarding Poland’s strategic initiatives in ensuring drug safety. He highlighted the need for a coherent strategy and substantial investments to drive significant progress in the pharmaceutical landscape. Cieszyński also touched upon the geopolitical tensions between the US and China, underscoring the potential ramifications for European countries caught in the middle.
Iwona Pająk, Director of Public Affairs at Novartis Poland, underscored the imperative of ramping up investments in healthcare to bolster the European pharmaceutical sector’s competitiveness. She stressed the importance of incentivizing R&D, nurturing strong industrial ecosystems, and embracing digital tools and AI to foster innovation. Pająk emphasized the fundamental shift needed in viewing healthcare not just as a social good but as a strategic asset vital for economic growth.
Justin Gandy, managing director of MSD Poland, emphasized the need for Europe to leverage its strengths in specialists, knowledge, and infrastructure to enhance pharmaceutical competitiveness. He advocated for long-term investment strategies and collaborative partnerships across the EU to tackle challenges collectively. Gandy urged a shift towards prioritizing long-term benefits over short-term costs to drive sustainable growth in the pharmaceutical industry.
As the panel discussion unfolded, it became evident that a cohesive approach encompassing robust legislation, strategic investments, and cross-border cooperation is essential for Europe to fortify its pharmaceutical industry. The lessons learned from the pandemic underscored the critical importance of unity and collaboration in tackling global health challenges.
Looking ahead, the participants recognized the need for a comprehensive strategy to bolster Europe’s pharmaceutical resilience and competitiveness. By aligning legislative frameworks, investment priorities, and collaborative efforts, Europe can strive towards bridging the gap with the US and reducing its reliance on external sources for essential medicines.
In conclusion, the dialogue at the Economic Forum in Karpacz highlighted the intricate web of factors influencing Europe’s pharmaceutical landscape. From regulatory reforms to geopolitical tensions, the pharmaceutical sector stands at a crucial juncture requiring concerted efforts and visionary leadership to navigate the complexities of the modern healthcare ecosystem.
Takeaways:
– Europe’s pharmaceutical industry is at a crossroads, balancing innovation, drug safety, and competitiveness amidst global challenges.
– Strategic investments, robust legal frameworks, and cross-border collaboration are pivotal in enhancing Europe’s pharmaceutical resilience.
– The pandemic underscored the importance of unity and cooperation in addressing healthcare crises, emphasizing the need for a cohesive approach in the pharmaceutical sector.
– Long-term vision, prioritizing innovation, and fostering public-private partnerships are key to driving sustainable growth in Europe’s pharmaceutical industry.
– Europe must reduce dependence on external sources for medicines, strengthen local manufacturing capabilities, and align legislative efforts to fortify its pharmaceutical sector.
– A strategic roadmap encompassing legislative reforms, investment incentives, and collaborative initiatives is essential for Europe to bridge the gap with the US and bolster its pharmaceutical competitiveness.